clinical results

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.

Cogent Biosciences presented expanded SUMMIT trial data showing bezuclastinib achieved significant symptom reduction and tryptase normalization in systemic mastocytosis patients, supporting its FDA regulatory applications.

Genenta rebrands to Saentra Forge, shifting focus toward defense and aerospace acquisitions while maintaining biotech research programs with glioblastoma trial results accepted for publication.